Investors who hold shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) Long Term should contact the Shareholders Foundation in connection with Investigation over potential Wrongdoing

An investigation was announced for current long-term investors in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) concerning potential breaches of fiduciary duties by certain directors of Pacira BioSciences, Inc.

Investors who are current long term investors in Pacira BioSciences, Inc. (NASDAQ: PCRX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: PCRX stocks follows a lawsuit filed against Pacira BioSciences, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: PCRX stocks, concerns whether certain Pacira BioSciences, Inc. directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the District of New Jersey the plaintiff alleges that, the defendants made false and/or misleading statements and/or failed to disclose that defendants created the false impression that Pacira had sufficient patent protections on Exparel, and as such, the ability to expand the marketing, production, and sales of Exparel, which Pacira stated was critical to its future growth and revenue, that Pacira knew that the '495 patent was not as protective as Pacira publicly touted because on June 6, 2023, the United States District Court for the District of New Jersey issued a ruling in eVenus Pharmaceutical Laboratories, Inc.'s favor regarding claims construction in another case filed by Pacira in a failed attempt to protect Exparel, and that therefore, when the '495 patent was invalidated in another case Pacira filed against eVenus, investors and analysts alike were shocked by the concerning news that Exparel, which accounts for approximately 80% of Pacira's revenue, did not have sufficient patent protection to prevent another company from producing a generic during the life of the patent.

Those who purchased shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.